Abstract: . . .  eject blood. Most patients with heart failure have impaired left ventricular (LV) func- tion, or systolic dysfunction, although diastolic dysfunction is common. Dyspnea, fatigue, and fluid retention resulting in impaired exercise tolerance, pulmonary congestion, and periph- eral edema are the major manifestations of heart failure. Functional capacity can be greatly affected. As with objective measures of myocar- dial ischemia, there can be a poor relationship between measures of cardiac performance (ejection fraction [EF]) and symptomatology. Persons with preserved LVEF (>5060%) can have disabling symptoms, while persons with highly compromised LVEF (<3040%) may be asymptomatic (Hunt et al. 2005). Heart failure is most commonly classified using the New York Heart Association (NYHA) func- tional classification. Like the CCS for angina , patients are classified into 1 of 4 classifications . . .
. . .  difference (p=0.01) between groups in the change in time to =1 mm ST-segment depression. Patients in the ECP group had an average difference of 37 seconds longer time to ST-segment depression compared to the sham- treated group. There was no significant differ- ence between treatment groups in the change in exercise duration from baseline to the post- treatment period (p<0.31). Additionally, there were no statistically significant differences between groups with respect to angina counts (p<0.09) or nitroglycerin usage (p>0.1). The ECP group experienced both more device- related (p<0.001) and non-device-related (p<0.005) events than the inactive CP group. Device-related events included more pain in the legs and back (28% for ECP versus 11% for the inactive CP) and skin abrasions (18% versus 3%, respectively). Two of the ECP patients experienced edema and swelling.  . . .
. . .  anginal episodes is problematic because of the large number of cells with low Page 15 2005 Blue Cross and Blue Shield Association. Reproduction without prior authorization is prohibited. 15 External Counterpulsation for T reatment of Chronic Stable Angina Pectoris and Chronic Heart Failure Table 6. Results of the MUST-EECP Trial: Adverse Experiences Associated with Treatment (Arora et al. 1999) Adverse Events Inactive CP (n=66)  . . .
--3000,3,500,2961,64618